Biological
Igrelimogene litadenorepvec clinical trials
Also written TILT-123.
- studies test it
- 5
- open now
- 0
- in phase 3
- 0
- first study started
- 2020
How studies write it
Studies that test it under each name
Development codes
Studies by the year they started
5 studies that test it; most in 2020 (1)
| Year | Studies |
|---|---|
| 2020 | 1 |
| 2021 | 1 |
| 2023 | 1 |
| 2024 | 1 |
| 2025 | 1 |
By phase
A phase 1/2 study counts in both.
- Phase 1
- 5
What it is tested for
Each study’s main condition, where its own words name it.
Who runs them
Industry 5 · Other 0
TILT Biotherapeutics Ltd. (5)
Often tested with
Tested in the same studies.
Avelumab (1) · Lymphocytes, Tumor-Infiltrating (1) · Therapeutic Tumor Infiltrating Lymphocytes (1) · Pembrolizumab (1)
Studies
Open first, then newest update. How each study uses igrelimogene litadenorepvec is read from its arms, and is right about nine times in ten.
Testing it · 5
- Oncolytic Adenovirus TILT-123 and Avelumab for Treatment of Solid Tumors Refractory to or Progressing After Anti-PD(L)1Active, not recruitingPhase 1TILT Biotherapeutics Ltd.NCT05222932Written as TILT-123
- TNFα and IL-2 Coding Oncolytic Adenovirus TILT-123 MonotherapyCompletedPhase 1TILT Biotherapeutics Ltd.NCT04695327Written as TILT-123
- TNFα and IL-2 Coding Oncolytic Adenovirus TILT-123 With Lymphocyte-depleting Chemotherapy and TILs in the Treatment of MelanomaActive, not recruitingPhase 1TILT Biotherapeutics Ltd.NCT06961786Written as TILT-123
- Oncolytic Adenovirus TILT-123 With Pembrolizumab as Treatment for Refractory Non-Small Cell Lung CancerActive, not recruitingPhase 1TILT Biotherapeutics Ltd.NCT06125197Written as TILT-123
- TNFalpha and Interleukin 2 Coding Oncolytic Adenovirus TILT-123 During TIL Treatment of Advanced MelanomaCompletedPhase 1TILT Biotherapeutics Ltd.NCT04217473Written as TILT-123
Given in every arm · 1 — igrelimogene litadenorepvec is usual care beside what is tested
Codes
What other systems call igrelimogene litadenorepvec · ClinicalTrials.gg INT014818
- UNII (FDA) 484TEV85XSIGRELIMOGENE LITADENOREPVECOne source FDA
- NCI Thesaurus C175454Igrelimogene LitadenorepvecOne source FDA
| System | Code | Name there | Checked by |
|---|---|---|---|
| UNII (FDA) | 484TEV85XS | IGRELIMOGENE LITADENOREPVEC | One source FDA |
| NCI Thesaurus | C175454 | Igrelimogene Litadenorepvec | One source FDA |
“Confirmed” means two independent publishers link the code to this drug; “one source”, one does and its name agrees.